|Fate Therapeutics, Inc.|
3535 General Atomics Court
United States - Map
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a persons lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a persons lifespan. The companys products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
|Dr. Christian Weyer M.D., MAS-CLRE,
Chief Exec. Officer, Pres and Director
|Mr. J. Scott Wolchko ,
Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer, Treasurer and Sec.
|Dr. Pratik S. Multani M.D., M.S.,
Chief Medical Officer
|Dr. Daniel D. Shoemaker Ph.D.,
Chief Technology Officer
|Ms. Cindy R. Tahl J.D.,
VP of Intellectual Property and Sr. Corp. Counsel
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|